Sorry, you need to enable JavaScript to visit this website.

Compensation to Investigators in Clinical Studies

Pfizer compensates investigators for providing protocol-required services for Pfizer-sponsored studies.

Compensation must be:

  • Fair, reasonable, and equitable to fair market value.
  • Explicitly identified in the investigator contract and linked to their performing specific and necessary protocol-required services (e.g., medical procedures, collection of data).
  • Specified in the informed consent that the investigator is being compensated by Pfizer.

Compensation must not be tied to the outcome of studies or include:

  • Pfizer stock or stock options.
  • Payments to physicians outside a study for referring subjects to investigators for entry into that study.
  • Any services performed by an investigator outside of the study (e.g., consulting services, honoraria, speaking engagements). These must be documented in a separate agreement.
  • Compensation for authorship of a primary publication about the results of the study.
  • Advanced payments in the United States.